Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.72 - $14.77 $399,256 - $1.03 Million
69,800 Added 601.72%
81,400 $679,000
Q2 2024

Aug 14, 2024

SELL
$1.86 - $6.98 $37,944 - $142,392
-20,400 Reduced 63.75%
11,600 $79,000
Q1 2024

May 15, 2024

SELL
$1.5 - $3.41 $2,550 - $5,797
-1,700 Reduced 5.04%
32,000 $80,000
Q4 2023

Feb 14, 2024

BUY
$1.82 - $3.16 $4,914 - $8,532
2,700 Added 8.71%
33,700 $80,000
Q3 2023

Nov 14, 2023

SELL
$3.17 - $7.91 $50,403 - $125,769
-15,900 Reduced 33.9%
31,000 $105,000
Q2 2023

Aug 14, 2023

SELL
$7.35 - $13.21 $385,140 - $692,204
-52,400 Reduced 52.77%
46,900 $344,000
Q1 2023

May 15, 2023

BUY
$7.79 - $16.29 $617,747 - $1.29 Million
79,300 Added 396.5%
99,300 $1.03 Million
Q4 2022

Feb 14, 2023

BUY
$11.0 - $21.45 $92,400 - $180,180
8,400 Added 72.41%
20,000 $236,000
Q3 2022

Nov 14, 2022

SELL
$20.09 - $35.8 $658,952 - $1.17 Million
-32,800 Reduced 73.87%
11,600 $243,000

Others Institutions Holding EBS

About Emergent BioSolutions Inc.


  • Ticker EBS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,861,500
  • Market Cap $443M
  • Description
  • Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emergi...
More about EBS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.